皮质类固醇和COVID-19导致的严重疾病后的长期肺功能 - 一个单中心队列研究
Mari Roël1,2, Anna Schandl3,4, Sandra Jonmarker3,4
1Department of Internal Medicine, Södersjukhuset, Stockholm, SE-118 83, Sweden. mari.roel@ki.se.
BMC pulmonary medicine
|April 26, 2025
概括
皮质类固醇可能会损害严重的COVID-19幸存者的肺功能. 这种对肺功能的影响没有影响他们的生活质量,在ICU退院后的六个月.
科学领域:
- 肺部病理学 肺部病理学
- 关键护理医学 关键护理医学
- 药理学 药理学是指药理学的学科.
背景情况:
- 在大流行期间,皮质类固醇成为严重COVID-19的标准治疗方法.
- 在通风COVID-19患者中调查皮质类固醇对肺的长期影响至关重要.
研究的目的:
- 在需要机械通风的危急COVID-19患者中评估皮质类固醇治疗的长期肺部后果.
- 评估对一氧化碳扩散能力和与健康有关的生活质量的影响.
主要方法:
- 观察性,单中心队列研究,ICU出院后6个月的随访.
- 肺功能通过一氧化碳 (DLCO) 扩散能力来评估.
- 使用RAND-36问卷测量与健康相关的生活质量.
主要成果:
- 在ICU治疗6个月后,皮质类固醇治疗与DLCO (8.3 MSD;95% CI: -14.2至 -2.4) 的降低有关.
- 超过10%的DLCO下降被认为具有临床意义.
- 两组之间没有观察到与健康有关的生活质量的显著差异.
结论:
- 皮质类固醇可能对COVID-19危急后的肺功能产生负面影响.
- 观察到的肺功能下降并没有影响与健康有关的生活质量.
- 需要进一步的研究来验证这些发现.
相关概念视频
COPD: Management Using Bronchodilators and Corticosteroids
117
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
117
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
131
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
131
COPD: Pathogenesis and Clinical Features
170
Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that progressively worsen over time, including chronic bronchitis and emphysema. This cluster of diseases collectively leads to a gradual and irreversible decline in lung function over time.
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
170
Pulmonary Tuberculosis I
198
Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
198
Chronic Obstructive Pulmonary Disease-I: Introduction
2.7K
Chronic Obstructive Pulmonary Disease (COPD) is a long-lasting respiratory condition requiring continuous attention and care. It is a progressive lung disease that leads to breathing challenges due to airflow obstruction. It manifests as persistent respiratory symptoms and restricted airflow resulting from abnormalities in the airways and alveoli, usually due to long-term exposure to harmful particles or gases. COPD mainly consists of two primary conditions: emphysema and chronic bronchitis.
2.7K
Chronic Obstructive Pulmonary Disease-V: Management
2.5K
Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
Smoking Cessation
2.5K


